Phaseline

Targets › COQ10

COQ10: drug programs, companies and trials

5 programs from 5 companies in 5 trials: 2 Phase 2, 2 Phase 3, 1 Phase 4; Neurology, Cardiovascular, Respiratory; next expected readout Dec 2026.

Open in Phaseline: the race on COQ10, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The Second Affiliated Hospital of Chongqing Medical UniversityCoenzyme Q10
Mitochondrial electron transport chain cofactor; may reduce oxidative stress and inflammat
COQ10Phase 4Postoperative Pain–
University of California, San DiegoPharmaNord Bio-Quinone Active CoQ10 Gold 100mg
Coenzyme Q10 (ubiquinone) supplementation
COQ10Phase 3Gulf War SyndromeDec 2027
Second Affiliated Hospital, Zhejiang University, School of MedicineIdebenone
Mitochondrial energy metabolism enhancer; improves cellular energy production through impr
COQ10Phase 3Migraine Disorders–
Medical College of WisconsinMitoQ
Mitochondrial-targeted antioxidant (ubiquinone derivative)
COQ10Phase 2StrokeDec 2026
George Washington UniversityCoQ10 1200 mg
Mitochondrial electron transport chain cofactor with antioxidant properties
COQ10Phase 2Renal FailureJun 2027

Conditions

Renal Failure (1) Gulf War Syndrome (1) Migraine Disorders (1) Stroke (1) Postoperative Pain (1)

Modalities

small molecule (4)

Companies

George Washington University (1) University of California, San Diego (1) Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Medical College of Wisconsin (1) The Second Affiliated Hospital of Chongqing Medical University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.